Shin Nippon Biomedical Laboratories, Ltd. Revises Earnings Forecast — Operating Profit Surges 167.8%

Shin Nippon Biomedical Laboratories, Ltd. Revises Earnings Forecast — Operating Profit Surges 167.8%

Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395) has raised its earnings guidance for the fiscal year ending March 2027’s interim period (April–September 2026), citing stronger-than-expected performance in its contract research organization (CRO) business and favorable foreign exchange movements.

The company attributed the upward revision to robust CRO business momentum, which is driving revenue above prior expectations. Operating profit benefited additionally from a timing shift in expense recognition within the translation and research (TR) segment, with costs now expected to be recorded in the second half of the fiscal year. Ordinary income (keijo rieki), a Japan-specific profit metric that includes non-operating items, was further boosted by JPY 172M in foreign exchange gains realized in the first quarter—an amount not previously anticipated. The company maintained its assumed USD/JPY exchange rate at 150.00.

The substantial 167.8% increase in operating profit signals that business execution is materially outpacing initial forecasts, particularly in the CRO division. The combination of operational strength and favorable timing of expenses and currency gains has lifted net profit guidance by 64.3%, translating to earnings per share of JPY 46.04/share, up from JPY 28.03/share. International investors should note that ordinary income differs from operating profit due to Japan’s accounting conventions and includes financial income and expenses. The revision underscores improving operational leverage in the company’s core research services business.

Source: Original filing (TDnet) | 日本語版

This article is for informational purposes only and does not constitute investment advice. Always verify against the original filing.